{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-progestogen-only-methods/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3d3ddcb9-bbef-5443-9762-08bf7c296da4","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 8f5f17c0-f60f-460d-9ec3-cfa926ae7b48 --><h2>Changes</h2><!-- end field 8f5f17c0-f60f-460d-9ec3-cfa926ae7b48 -->","summary":null,"htmlStringContent":"<!-- begin item cd3809ef-0c1a-4224-a625-a6d5a273f949 --><!-- begin field a7e8fa21-5d11-4185-acdc-3ddc00f73535 --><p><strong>November 2019</strong> – minor update. A typographical error was corrected.  </p><p><strong>March 2019</strong> — minor update. A pill should now be considered missed if there is more than a 2 hour delay in it being taken (26 hours since taking the last pilll) or if vomiting occurs within 2 hours of taking the pill.</p><p><strong>June 2018</strong> — minor update. Panic attacks have been added to adverse effects for people taking desogestrel. </p><p><strong>December 2017</strong> — minor update. Update to add information about fetal malformations and effectiveness of hormonal contraceptives as an effect of topiramate.</p><p><strong>February 2017</strong> — minor update.</p><ul><li>The information on drug interactions has been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Drug interactions with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2017a</a>]. </li><li>Recommendations on when to start progestogen-only contraception after pregnancy, miscarriage, or termination of pregnancy have been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Contraception after pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2017b</a>].</li></ul><p><strong>June to July 2016</strong> — reviewed. A literature search was conducted in June 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor structural changes have been made.</p><!-- end field a7e8fa21-5d11-4185-acdc-3ddc00f73535 --><!-- end item cd3809ef-0c1a-4224-a625-a6d5a273f949 -->","topic":{"id":"9ff99c6b-985a-5146-8ef5-665fc2b551bb","topicId":"832bfe6c-0c1e-4dca-89eb-7e914cf17833","topicName":"Contraception - progestogen-only methods","slug":"contraception-progestogen-only-methods","lastRevised":"Last revised in November 2019","chapters":[{"id":"e97a1889-5b3c-51c7-abca-435669821908","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9d1ba26b-0889-5782-a5dd-876d8d8965c8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e40c82f2-3cbd-56c2-b06f-b2d3bfae8a34","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3d3ddcb9-bbef-5443-9762-08bf7c296da4","slug":"changes","fullItemName":"Changes"},{"id":"5c8ed192-6ffb-5084-a621-3d1b14ea264d","slug":"update","fullItemName":"Update"}]},{"id":"c2b04259-e45f-54ea-ba94-5bc43975229b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c2cce341-0179-531a-bea7-9b8f9120b8c0","slug":"goals","fullItemName":"Goals"},{"id":"8aa31475-0c4c-5b7a-bbb7-82a288b1541c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"59f5527f-5091-5084-ab85-34cd87ab3424","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"14b43b64-8b02-5470-a6a1-41982cbed802","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1cd2c043-e2cd-5c97-9a82-32c5baf9f590","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71e31498-8434-55e9-9802-459d2ed956f5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"62d7d86a-7652-51fb-972e-f8113766a58c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ba99afb9-717a-59e6-b0af-a6fe316f6e0b","slug":"where-to-get-progestogen-only-contraception","fullItemName":"Where to get progestogen-only contraception"}]},{"id":"74f87f5c-2983-599c-9881-ad5d663100c0","fullItemName":"Management","slug":"management","subChapters":[{"id":"28c180bd-05b7-5bf7-8601-f61802a3f2b0","slug":"progestogen-only-pill","fullItemName":"Scenario: Progestogen-only pill"},{"id":"4c571c2d-718a-5351-ba2b-f3c8d69a15c4","slug":"progestogen-only-implant","fullItemName":"Scenario: Progestogen-only implant"},{"id":"a3632aab-62ce-5263-b365-24e12194e389","slug":"progestogen-only-injectables","fullItemName":"Scenario: Progestogen-only injectables"}]},{"id":"b040c0e0-cf32-51f5-8b09-18bca20a90c8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0b3c54f3-29e8-5d1b-af69-397a9b27760f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"654d1af0-9c4c-5d0a-90e6-d8cd8063b1c6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b1383200-8981-5368-ba45-a0d6bbbe92a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"05903434-c83e-5971-964b-85a3d8d7e8b3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3f865d6-8f60-5c7a-b522-6e18d274c84c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"39d2eca9-efb9-5f08-b73b-15fb2a3d4896","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d93103c6-16a2-5c1d-92ce-7a991173c791","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e40c82f2-3cbd-56c2-b06f-b2d3bfae8a34","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f48a1295-0492-57b3-a138-24ddca288555","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d241801e-03b9-48c0-8a56-30702a93496b --><h3>Previous changes</h3><!-- end field d241801e-03b9-48c0-8a56-30702a93496b -->","summary":null,"htmlStringContent":"<!-- begin item e77198a7-06a6-4c91-9a04-bb1aa95d0886 --><!-- begin field 4f3be4a4-4e94-4a2d-ab5f-6aa5de1acc93 --><p><strong>February 2015</strong> — minor update. Update to the text to reflect changes in the Summary of Product Characteristics (SPC) regarding the risk of the progestogen-only implant breaking or bending in situ.</p><p><strong>March 2014</strong> — minor update. Update to the text to reflect new guidance from the Medicines and Healthcare products Regulatory Agency (MHRA)(2014) regarding St John's wort and women using hormonal contraceptives.</p><p><strong>March 2014</strong> — minor update. Update to the text to include the new depot medroxyprogesterone acetate injection, Sayana Press® as a prescribing option.</p><p><strong>June 2013 </strong>— minor update. The 2013 Quality and Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>May 2013 </strong>— minor update to the text to reflect recent advice issued by the Faculty of Sexual and Reproductive Healthcare (FSRH) (2013) regarding the interaction between progestogen-only implants and newer antiepileptics.</p><p><strong>March 2013 </strong>— minor update. The telephone number for NHS Direct has been updated.</p><p><strong>January 2013</strong> — minor update. Change to the text to reflect updated advice from the FSRH (2012) regarding the interaction between Esmya® and hormonal contraceptives.</p><p><strong>February to June 2012</strong> — revised. A literature search was conducted in December 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations have been made. However, recommendations have been rewritten for clarity, and superseded guidelines and manufacturers' SPCs have been updated accordingly.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>February 2011</strong> — minor update. The FSRH (2011) no longer recommend that additional contraceptive precautions are required during or after courses of antibiotics that do not induce liver enzymes. However, additional contraceptive precautions are required if the antibiotic or illness causes vomiting or diarrhoea.</p><p><strong>November 2010</strong> — minor update. Advice from the FSRH (FSRH, 2010) guideline <em>Quick starting contraception</em> has been included in this topic.</p><p><strong>October 2010 </strong>— minor update. Update to include information from an FSRH statement (2010) that Nexplanon® will replace Implanon® as the only progestogen-only implant licensed for use in the UK. Nexplanon® and Implanon® are bioequivalent (both contain 68 mg etonogestrel, have the same release rate, and provide contraception for 3 years). The main differences are that Nexplanon® is radio-opaque, and has a different application device and insertion technique (training is required).</p><p><strong>March 2010</strong> — minor update. Prescribing information sections updated in line with the FSRH (FSRH, 2010) statement on antiepileptic drugs and contraception. Advice from the Department of Health (2010) regarding assessment of young women aged under 24 years with abnormal vaginal bleeding also added.</p><p><strong>February 2010</strong> — updated to include the revised FSRH (2010) <em>UK medical eligibility criteria for contraceptive use</em>.</p><p><strong>March 2009</strong> — minor update. The 2009 QOF indicators for sexual health have been updated in the Goals and outcome measures section. </p><p><strong>February 2009</strong> — updated to include recent guidance from the FSRH (FSRH, 2009) on Progestogen-only pills and Progestogen-only injectable contraception; advice on when to suspect uterine perforation following insertion of an intrauterine device or system has been updated; and the upper age limits on the prescriptions for combined oral contraceptive pills have been changed to 50 years. </p><p><strong>May 2008</strong> — update to text to reflect new guidance from the FSRH (FSRH, 2008), on progestogen-only implants.</p><p><strong>April to September 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2006</strong> — minor update. Information regarding orlistat and reduced efficacy of oral contraceptives included in drug interactions. Issued in July 2006.</p><p><strong>January 2006</strong> — minor update. Gynol II Jelly®, Microval® tablets and Duragel® have been discontinued and the prescriptions have been removed. Black triangle status removed from Cerazette®. </p><p><strong>October 2005</strong> — updated to include the new recommendations on missed pills from the Faculty of Family Planning and Reproductive Healthcare Clinical Effectiveness Unit (2005).</p><p><strong>April 2005</strong> — minor update. Neogest® tablets have been discontinued and the prescriptions have been removed.</p><p><strong>February 2005</strong> — updated to include prescribing advice from the Committee on Safety of Medicines (CSM) on the effect of depot medroxyprogesterone acetate contraception on bones. Issued in February 2005.</p><p><strong>September 2004</strong> — updated to include the World Health Organization (WHO) Medical Eligibility Criteria relating to contraception for 2004 and recent licence changes to Cerazette®. Delfen® Contraceptive Foam is being discontinued at the end of October 2004 and the prescriptions have been removed. Issued in September 2004.</p><p><strong>January 2004 </strong>— reviewed. Validated in March 2004 and issued in June 2004.</p><p><strong>January 2001</strong> — rewritten. Validated in March 2001 and issued in June 2001. Guidance on emergency contraception is no longer included in the Contraception guidance but can be found as a separate CKS topic.</p><p><strong>December 1997</strong> — written.</p><!-- end field 4f3be4a4-4e94-4a2d-ab5f-6aa5de1acc93 --><!-- end item e77198a7-06a6-4c91-9a04-bb1aa95d0886 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}